

Notice

An Act respecting prescription drug insurance
(chapter A-29.01)

End of coverage of medications

HAVING REGARD TO section 60.0.4 of the Act respecting prescription drug insurance
(chapter A-29.01);

HAVING REGARD TO the power of the Minister to suspend the insurance coverage of a medication, to end it or to not re-register it, notably where a medication is subject to a registration agreement;


HAVING REGARD TO the power of the Minister to maintain the insurance coverage of a medication pursuant to paragraph 3 of section 60.0.4 of the Act respecting prescription drug insurance (chapter A-29.01);

CONSIDERING that the medication Basaglar™, a competitor to the medication Lantus™, is the subject of a listing agreement pursuant to subparagraph 3 of paragraph 1 of section 60.0.4 of the Act respecting prescription drug insurance;

The Minister of Health and Social Services hereby gives notice of the end of the insurance coverage of the medication Lantus™ in S.C. Inj. Sol. 100U/ml (3 ml) and in Solostar™ S.C. Inj. Sol. 100U/ml (3 ml) except with regard to those eligible persons who began a treatment and received a reimbursement for this medication from the Régie or an insurer or via the administrator of an employee benefit plan before 18 August 2017 under item 4 or item 6 of Schedule 1 to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan(chapter A-29.01, r. 3).

This Notice will come into force on 18 August 2017.

Québec, **28 JUIL. 2017**



GAËTAN BARRETTE
Minister of Health and Social Services